Quadrant Private Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Quadrant Private Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243K	Buy	+489	New	+$217K	0.05%	144
2020 Q3	–	Sell	-698	Closed	-$203K	–	187
2020 Q2	$203K	Sell	698 -628	-47%	-$170K	0.12%	166
2020 Q1	$316K	Buy	+1,326	New	+$304K	0.26%	88

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Quadrant Private Wealth Management's VRTX Position: Q2 2026 in Review

Quadrant Private Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 489 shares worth $243K. The stake represents 0.05% of the portfolio and ranks #144 among its holdings. This is a return to the name: Quadrant Private Wealth Management previously reported a position in VRTX as recently as Q2 2020.

Quadrant Private Wealth Management first reported a position in VRTX in Q1 2020 and has held it in 3 quarters since. The position peaked at $316K in Q1 2020. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Quadrant Private Wealth Management held 489 shares of Vertex Pharmaceuticals worth $243K as of Q2 2026.
Vertex Pharmaceuticals was a new Quadrant Private Wealth Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.05% of Quadrant Private Wealth Management's portfolio in Q2 2026, its #144 holding.
Quadrant Private Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 3 quarters since.
Quadrant Private Wealth Management's Vertex Pharmaceuticals position peaked at $316K in Q1 2020.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Quadrant Private Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.